Who Paid My Doc
Wendy De La Pena
Pediatric Rheumatology San Bernardino, CA Medical Doctor
NPI 1407890429 CMS profile 245706
2195 Club Center Dr Ste G, Dept 3900, San Bernardino, CA 92408
General payments
$2,260
Research payments
$4,470
Ownership & investment interest
$0
Research they led as principal investigator
$103,386
Through program year 2025, Wendy De La Pena of San Bernardino, CA is reported in the CMS Open Payments database as having received $2,260 across 74 general payments and $4,470 in research payments paid to them. Separately, studies naming them as principal investigator received $103,386 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 83rd percentile of Pediatric Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
9 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $71 | 3 | |
| 2024 | General | $349 | 18 | |
| 2023 | General | $598 | 18 | |
| 2023 | Research | $3,200 | 1 | |
| 2022 | General | $141 | 8 | |
| 2021 | General | $233 | 6 | |
| 2020 | General | $354 | 11 | |
| 2020 | Research | $1,270 | 2 | |
| 2019 | General | $513 | 10 |
Beside peers
- Wendy De La Pena
- Pediatric Rheumatology median
- Middle half of Pediatric Rheumatology
- National median
In program year 2025, general payments to Wendy De La Pena were reported at $71. Among 204 Pediatric Rheumatology profiles paid that year, the median was $146 and the middle half received between $95 and $522.
Show as a table
| Year | Wendy De La Pena | Pediatric Rheumatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $513 | $141 | $61–$1,029 | $163 |
| 2020 | $354 | $113 | $33–$419 | $114 |
| 2021 | $233 | $189 | $61–$1,640 | $132 |
| 2022 | $141 | $120 | $28–$404 | $149 |
| 2023 | $598 | $97 | $41–$222 | $160 |
| 2024 | $349 | $139 | $48–$606 | $164 |
| 2025 | $71 | $146 | $95–$522 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
77 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Rheumatology in California
William Soulsby
Pediatric Rheumatology · San Francisco, CA
Vivian Saper
Pediatric Rheumatology · Palo Alto, CA
Jennifer Frankovich
Pediatric Rheumatology · Palo Alto, CA
Andrew Shulman
Pediatric Rheumatology · Orange, CA
Peter Chiraseveenuprapund
Pediatric Rheumatology · San Diego, CA
Andreas Reiff
Pediatric Rheumatology · Los Angeles, CA
Related records
Pediatric Rheumatology in California
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Rheumatology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.